No image published for this recall
Oestrogen replacement therapy and increased risk of ovarian cancer - safety alert
Official notice
25 May 2026
Last checked
25 May 2026
An official TGA notice concerns Oestrogen replacement therapy and increased risk of ovarian cancer - safety alert. An official TGA notice concerns Oestrogen replacement therapy and increased risk of ovarian cancer. The notice reports a potential product safety risk. Follow the official notice for consumer instructions. Published 2026-05-25. Published 2026-05-25.
What to do now
The source does not provide specific consumer instructions. Follow the official TGA notice for next steps.
Recall number
283862
Official notice
2026-05-25
The hazard
The hazard
An official TGA notice concerns Oestrogen replacement therapy and increased risk of ovarian cancer. The notice reports a potential product safety risk. Follow the official notice for consumer instructions. Published 2026-05-25.
Checked manually this time?
The app alerts you when a new official recall is published — no searching, no checking back.
Turn on recall alertsAffected products
Affected products
Product 1
Risk / hazard
Where it was sold
Where it was sold
The source does not list specific retailers. See the official notice for where affected products were sold.
Location 1
Affected area 1
Company & contacts
Company & contacts
Manufacturer
Phone
Contact: Therapeutic Goods Administration (TGA).
Source & status
Source & status
Recall details
Recall details
Recall number
Event id
Source tier
Documents, notices & source
See the official notice and source documents for full details.
View full official noticeRelated recalls
Herbal preparations containing Withania somnifera (Withania, Ashwagandha) - safety alert
7 Jul 2026Caffeine and oxedrine containing products - safety alert
GNY Australia products: MSV Strong Version, ESV Extra Strong Version and RL Rapid Loss soft gel capsules - safety alert
Sanoma Garden - various therapeutic goods - safety alert
Camellia sinensis (green tea) extract - safety alert
Hydroxyethyl starch (Voluven and Volulyte) - safety alert
Sodium glucose co-transporter 2 inhibitors - used to treat type 2 diabetes - safety alert
Non-steroidal anti-inflammatory drugs (NSAIDs) review - safety alert
Ivabradine (Coralan) and cardiovascular events in patients with angina - safety alert
Domperidone (Motilium) and effects on the heart - safety alert
Hydroxyethyl starch (Voluven and Volulyte) and increased risk of mortality - safety alert
Apixaban (Eliquis), dabigatran (Pradaxa) and rivaroxaban (Xarelto): Information for health professionals - safety alert
GNY Australia products: MSV Strong Version, ESV Extra Strong Version and RL Rapid Loss soft gel capsules - safety alert
Weekly recall digest
Get next week's recalls before you need them.
One email every Monday — official-source recalls for your country, and nothing else. Unsubscribe from any email.
The digest is the slow lane — one email a week. For instant, severity-gated alerts the moment a notice is published, get the app.
This recall was published 25 May 2026. The next one won't wait for you to search.
RecallScope watches official sources for the brands and VINs you follow, and alerts you the moment a new notice is published.
